Navigation Links
Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009

SAN FRANCISCO, Sept. 21 /PRNewswire/ -- The TCT 2009 meeting will feature an unusual amount of novel information about Vulnerable Coronary Artery Plaque, the structure widely considered to be the primary cause of acute coronary events, the leading cause of death in the developed world. The concept of Vulnerable Plaque has been a topic of study for over 2 decades. TCT will showcase progress on a number of diagnostic catheters designed to identify the lipid core plaques that are widely suspected to be vulnerable.

  • Monday, September 21 -- Four presentations in the day-long Vulnerable Plaque Symposium describing the experience with LipiScan, a novel near-infrared spectroscopy catheter (InfraReDx, Inc.) approved in 2008 by the FDA for identification of lipid core plaques. (Room 131)
  • Thursday, September 24 -- Dr. Gregg Stone will present the results of the 3 year follow-up of suspected vulnerable plaques in the Prospect Trial, a study of over 700 patients with multi-vessel ultrasound (Virtual Histology, Volcano, Inc.) measurements at baseline. This major trial is the first, large, long-term study of the hypothesis that harmful vulnerable plaques can be identified before they cause a coronary event. (Room 300)

In 1989, Dr. James Muller and colleagues introduced the term "Vulnerable Plaque" to describe a plaque at high risk of disruption that leads to coronary thrombosis. Dr. Muller, CEO of InfraReDx, Inc. participated in the company's founding in 1998 for the purpose of developing a spectroscopic catheter to detect vulnerable plaque. Dr. Muller will be available at TCT to comment on the important developments related to vulnerable plaque reported at the meeting, including commentary on the outcome of the Prospect Trial. Dr. Muller and his colleague, Jim Dillon, Vice-President of Sales and Marketing at InfraReDx, Inc. will be available for comment on the use of the LipiScan system, the only FDA cleared product to detect lipid core plaque and the InfraReDx experience in over 400 patients. The commercially available LipiScan(TM) Coronary Imaging System will be displayed in the "Emerging Technologies" section at booth # 2410.

  • References
    • Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Clinical Progress Series. Circulation 1989; 79:733-743.
    • Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors, and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23:809-813.

About InfraReDx, Inc.

InfraReDx, Inc., headquartered in Burlington, Massachusetts, was founded in 1998 and is a privately-funded medical device company developing a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronary arteries. For more information, visit

About TCT 2009

Transcatheter Cardiovascular Therapeutics (TCT) is organized by the Cardiovascular Research Foundation, which is dedicated to research and education in the broad subspecialty of interventional cardiology and endovascular medicine. TCT is scheduled from Monday, September 21(st) to Friday, September 25(th), in San Francisco, CA. at the Moscone Center. This scientific meeting is one of the world's largest events for those performing cardiac diagnostics and interventions. This meeting is the primary annual meeting for the world-wide interventional cardiology community. For more information, visit

    Company Contacts:
    Dr. Muller Contact:     Investor Contact:      Media Contact:
    Carolyn Rogers          Jeff Mazur             Jim Dillon
    InfraReDx, Inc.         InfraReDx, Inc.        InfraReDx, Inc.
    (781) 345-9644          (781) 345-9626         (781) 345-9679

SOURCE InfraReDx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Web Site Will Help Pennsylvanians Learn About, Protect Against Novel H1N1 Flu
2. The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six-Fold to Over $3.2 Billion in 2018
3. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
4. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
5. Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
6. Solution to PREVENT Novel H1N1 (Swine Flu) From Closing Down Schools!
7. The Cosmetic Bootcamp LLC Announces Novel Presentations at Its 3rd Annual Marketing and Management Symposium
8. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
9. Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates
10. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
11. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
Post Your Comments:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology: